D&MD's Antibody Market Update analyzes the most important happenings of the last year, including recent collaborations and partnerships, successes and failures in late stage clinical trials, a complete update on several patent disputes, and a thorough review of the advances in discovery, manufacture, and processing of antibodies. 

This thorough update highlights all that is hot within this industry. Several market factors from last year point to a very bright future for the antibody market including: 

The antibody therapeutics market is expected to grow 30% annually, reaching over $7 billion by 2004.

Most of the growth in the sale of antibody therapeutics can be attributed to five antibodies: ReoPro®, Rituxan®, Remicade®, Synagis®, and Herceptin.®

Sixty-three new alliances involving several antibody and bio/pharmaceutical companies have been recorded.

The industry welcomes two new approved antibodies bringing the total up to 13 - many of which are forecasted to peak at over a billion dollars in annual sales.

By the middle of the decade, the demand for manufacturing of biotherapeutics will be in equilibrium with the available manufacturing capacity. 

Publication:  December 2002

Publisher: Drug and Market Development 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/DMD_2003.html#a63